re: morphosys news With all due respect Tony, PYC's technology...

re: morphosys news With all due respect Tony, PYC's technology or peptides cannot do either of the two things you suggested. They have no data showing that their peptides can cross cells and be active, in fact there are very few real examples of this from any of the peptide companies, and has been one of the biggest challenges. PYC's peptides are likely too big to target intracellular targets, regardless what they may want to claim. It is well known in the field, and it is also well known that they have no data. PYC's peptides could function to target a specific cell type by identifying peptides that bind to that cell type, and potentially serve to assist a molecule crossing into cells, maybe a small molecule drug, or maybe carry a payload into the brain by crossing the BBB. Companies have been working on getting antibodies into cells and released into cytoplasm to target intracellular targets for more than 20 years, with little progress (most get degraded in endosomes or not enough gets into cells to be functional), so it is not as easy as you suggest, and PYC has no data that they can do it any better than the currently available methods. THINK for a second, that if they really could do that, don't you think everyone would be working with them or have bought them out by now?? I mean the Roche, Pfizer, and MedImmune partnerships have all ended and those companies have 1) not licensed anything, and 2) not signed up to do additional targets. Those deals were nothing more than short-term Proof of Concept (POC) deals, which are standard starter contracts in the industry, where those companies took a test drive of what PYC could do, and the outcome looks like they weren't impressed. Jansen is the first multi-target multi-year deal they have announced, suggesting it may be more than just a POC contract, but time will tell.